Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade

Eli Lilly (LLY) stock recently declined 1.23% to $762.18, underperforming the broader market, despite robust consensus growth expectations for its upcoming August 7, 2025 earnings report. Analysts project a 41.58% year-over-year EPS increase to $5.55 and 28.53% revenue growth to $14.53 billion for the quarter, with full-year forecasts anticipating EPS up 69.28% to $21.99 and revenue up 33.48% to $60.12 billion, though recent EPS estimates saw a marginal 0.33% downward revision. LLY trades at a premium Forward P/E of 35.09 compared to its industry's 14.2, but its PEG ratio of 1.12 is slightly below the industry average of 1.24, and it currently holds a Zacks Rank of #3 (Hold).

Analysis

Eli Lilly (LLY) recently experienced a daily stock decline of 1.23% to $762.18, underperforming the S&P 500's modest gain, creating a disconnect with its exceptionally strong forward-looking fundamentals. Consensus estimates project significant growth, with the upcoming quarter's EPS and revenue expected to increase by 41.58% and 28.53% year-over-year, respectively. Full-year forecasts are even more robust, anticipating a 69.28% rise in earnings and a 33.48% increase in revenue. This growth narrative, however, is set against a premium valuation, evidenced by a Forward P/E ratio of 35.09, which is more than double the industry average of 14.2. The company's PEG ratio of 1.12, slightly below the industry average of 1.24, suggests this high valuation is largely a function of its powerful growth prospects. Despite the bullish forecasts, a subtle note of caution is warranted, as the consensus EPS estimate has been revised 0.33% lower over the past month, contributing to its neutral Zacks Rank #3 (Hold) rating.

Key Decisions for Investors

• Investors should weigh the company's exceptional earnings growth forecasts against its premium Forward P/E of 35.09, which implies that the market has already priced in significant future success.
• The recent minor downward revision to EPS estimates and the neutral 'Hold' rating suggest it may be prudent to monitor for any further negative analyst sentiment shifts ahead of the next earnings report.
• Consider the PEG ratio of 1.12 as a key metric; its position below the industry average suggests the stock's price may be reasonable relative to its high growth, but this thesis hinges on the company meeting or exceeding its ambitious financial targets.
• Given the recent daily underperformance against a rising market, investors could view this as either a potential entry point based on strong fundamentals or a sign of near-term consolidation as the market digests the high valuation.